Eli Lilly Signs an Exclusive Worldwide License Agreement with Centrexion Therapeutics for its CNTX-0290
Shots:
- Centrexion to receive $47.5M upfront- up to $950M as development- regulatory & commercial milestones and royalties on sales of product. Lilly to get exclusive WW rights for CNTX-0290 & will co-promote CNTX-0290 with Centrexion in the US
- The focus of the collaboration is to strengthen Lilly’s pain management portfolio and allow Centrexion to focus on new targets for chronic pain
- Centrexion’s CNTX-0290 is a somatostatin receptor type 4 (SSTR4) agonist- is being evaluated in P-I as a non-opioid treatment for chronic pain
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com